論文

国際誌
2021年7月

Subsequent systemic therapy for non-small cell lung cancer patients with immune checkpoint inhibitor-related interstitial lung disease.

Translational lung cancer research
  • Yusuke Sato
  • ,
  • Satoshi Watanabe
  • ,
  • Takeshi Ota
  • ,
  • Kohei Kushiro
  • ,
  • Toshiya Fujisaki
  • ,
  • Miho Takahashi
  • ,
  • Aya Ohtsubo
  • ,
  • Satoshi Shoji
  • ,
  • Koichiro Nozaki
  • ,
  • Kosuke Ichikawa
  • ,
  • Satoshi Hokari
  • ,
  • Rie Kondo
  • ,
  • Masachika Hayashi
  • ,
  • Hiroyuki Ishikawa
  • ,
  • Takao Miyabayashi
  • ,
  • Tetsuya Abe
  • ,
  • Satoru Miura
  • ,
  • Hiroshi Tanaka
  • ,
  • Masaaki Okajima
  • ,
  • Masaki Terada
  • ,
  • Takashi Ishida
  • ,
  • Akira Iwashima
  • ,
  • Kazuhiro Sato
  • ,
  • Hirohisa Yoshizawa
  • ,
  • Nobumasa Aoki
  • ,
  • Yasuyoshi Ohshima
  • ,
  • Toshiyuki Koya
  • ,
  • Toshiaki Kikuchi

10
7
開始ページ
3132
終了ページ
3143
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.21037/tlcr-21-198

Background: Although immune checkpoint inhibitors (ICIs) are effective for advanced non-small cell lung cancer (NSCLC), ICIs may cause interstitial lung disease (ILD), which results in treatment discontinuation and is sometimes fatal. Despite the high incidence of ICI-related ILD, there are few cancer treatment options for patients. This study aimed to evaluate the safety and efficacy of subsequent systemic cancer therapy in NSCLC patients with ICI-related ILD. Methods: We retrospectively assessed NSCLC patients who received programmed cell death-1 (PD-1) inhibitors as first- to third-line therapy at participating institutions of the Niigata Lung Cancer Treatment Group from January 2016 to October 2017. Results: This analysis included 231 patients, 32 (14%) of whom developed ICI-related ILD. Of these patients, 16 (7%) received subsequent systemic cancer treatments. The median overall survival (OS) tended to be longer in the systemic cancer therapy group than in the no systemic cancer therapy group [22.2 months (95% CI: 1-NE) vs. 4.5 months (95% CI: 1-NE); P=0.067]. ICI-related ILD recurred in half of the patients who received systemic cancer therapy, and the median OS tended to be shorter in patients with recurrent ICI-related ILD [22.0 months (95% CI: 1-NE) vs. 7.0 months (95% CI: 1-NE); P=0.3154]. Conclusions: According to the current study, systemic cancer treatment is effective in patients with ICI-related ILD; however, its safety is uncertain because of the high risk of ICI-related ILD recurrence and poor survival outcome following ILD recurrence.

リンク情報
DOI
https://doi.org/10.21037/tlcr-21-198
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/34430353
PubMed Central
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8350095
ID情報
  • DOI : 10.21037/tlcr-21-198
  • PubMed ID : 34430353
  • PubMed Central 記事ID : PMC8350095

エクスポート
BibTeX RIS